Clinical trial NCT03256045: Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Official title: CLBH589DUS108T: Panobinostat With Carfilzomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Correlation With In Vitro Chemosensitivity Testing
Conditions: Recurrent Plasma Cell Myeloma
Refractory Plasma Cell Myeloma
Summary: This phase II trial studies how well panobinostat, carfilzomib, and dexamethasone work in treating patients with multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory). Panobinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as carfilzomib and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Using multiple myeloma cells from patients' blood samples, the researchers will do laboratory tests to look at how well each of the drugs, alone and in different combinations, kill multiple myeloma cells. If the laboratory tests work well, they may be used in the future to help plan treatment for future patients.
Interventions:
description: Given IV
name: Carfilzomib
other_name: Kyprolis
PR-171
type: Drug
description: Undergo in vitro chemosensitivity testing
name: Chemosensitivity Assay
other_name: Chemosensitivity Testing
type: Other
description: Given PO
name: Dexamethasone
other_name: Aacidexam
Adexone
Aknichthol Dexa
Alba-Dex
Alin
Alin Depot
Alin Oftalmico
Amplidermis
Anemul mono
Auricularum
Auxiloson
Baycuten
Baycuten N
Cortidexason
Cortisumman
Decacort
Decadrol
Decadron
Decalix
Decameth
Decasone R.p.
Dectancyl
Dekacort
Deltafluorene
Deronil
Desamethasone
Desameton
Dexa-Mamallet
Dexa-Rhinosan
Dexa-Scheroson
Dexa-sine
Dexacortal
Dexacortin
Dexafarma
Dexafluorene
Dexalocal
Dexamecortin
Dexameth
Dexamethasonum
Dexamonozon
Dexapos
Dexinoral
Dexone
Dinormon
Fluorodelta
Fortecortin
Gammacorten
Hexadecadrol
Hexadrol
Lokalison-F
Loverine
Methylfluorprednisolone
Millicorten
Mymethasone
Orgadrone
Spersadex
Visumetazone
type: Drug
description: Correlative studies
name: Laboratory Biomarker Analysis
type: Other
description: Given PO
name: Panobinostat
other_name: Faridak
Farydak
LBH589
type: Drug
Study arms:
design_group_description: Patients receive panobinostat PO on days 1, 3, 5, 15, 17, and 19. Patients also receive carfilzomib IV and dexamethasone PO on days 1, 2, 8, 9, 15, and 16. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood and/or bone marrow samples for testing via in vitro chemosensitivity assay.
design_group_title: Treatment-panobinostat, carfilzomib, dexamethasone,chemo assay
design_group_type: Experimental
Sponsor: University of Washington
Collaborators: National Cancer Institute
Secura Bio, Inc.
Drug name mappings:
name: 乳酸帕比司他
lang: CN
name: Panobinostat lactate
lang: EN
name: パノビノスタット乳酸塩
lang: JP
name: 卡非佐米
lang: CN
name: Carfilzomib
lang: EN
name: カルフィルゾミブ
lang: JP
name: 地塞米松磷酸钠
lang: CN
name: Dexamethasone Sodium Phosphate
lang: EN
name: デキサメタゾンリン酸エステルナトリウム
lang: JP